Lithium (Li) is the gold standard treatment for bipolar disorder (BD), but only 30 % of patients respond very well. To date, there are no clinical or biological markers to reliably define eligibility criteria for lithium maintenance therapy. After exploring several mechanisms, we have turned our attention to epigenetic markers as biomarkers of response to Li in TB. The main advances of this research will be presented.
Cynthia Marie-Claire is a research director (DR2, CNRS). A molecular biologist, she has expertise in cell biology, biochemistry and data analysis " omiques ". She co-directs (with Pr Xavier Decleves) the research unit " Optimisation en neuropharmacologie " UMR-S 1144 and also (with Pr Frank Bellivier) the research team " Biomarkers of relapse and therapeutic response in neuropsychiatric diseases ". It studies the variability of treatment response in substance use disorders and mood disorders using biochemical and molecular approaches, including cellular models and methylomic, mirnomic, genetic and transcriptomic studies. The objectives are to better understand the mechanisms underlying variability in treatment response and the clinical determinants of clinical trajectories.
